Myeloma UK has developed a Clinical Trial Network of leading experts, hospitals and research centres across the UK to run a portfolio of prioritised clinical trials to accelerate the testing of, and access to, new myeloma treatments.
Clinical Trial Network
The aims of the Clinical Trial Network are to:
- Improve patient outcomes by developing and implementing strategic, clinically relevant and patient-centric clinical trials.
- Improve the efficiency and speed with which new trials are set up and completed.
- Produce results that change clinical practice through effective trial design and creating an environment that allows results to be adopted and diffused through the NHS as quickly as possible.
- Ensure early access to experimental novel treatments by making the UK an internationally competitive place to conduct research in myeloma.
Myeloma UK CEO, Eric Low, talks about the organisation’s latest clinical trial and how our Clinical Trial Network accelerates access to new treatments for myeloma patients.
Through increasing the speed at which novel drugs are tested and by ensuring that trial design reflects UK clinical practice and meets the needs of regulatory and reimbursement bodies as far as possible, we are increasing patient access to the newest and most innovative treatments in myeloma.
You can find out more information about the treatments involved and the current status of our trials in our clinical trials portfolio.
The Myeloma UK CTN is made up of a number of hospitals across the UK with a central Trial Office in Leeds. Trials are currently open for recruitment in London, Manchester, Leeds, Nottingham, Birmingham, Sheffield, Oxford, Southampton and Cardiff.
In our CTN, trials are developed and prioritised by a CTN Steering Group of myeloma specialists, clinical trials and statistics experts, partners from the NIHR and Myeloma UK Research Management. Every trial protocol is sent to members of the International Peer Review Panel to complete a formal review document. Comments from this review process are discussed and adopted as appropriate.